Brief: Astellas & Vir Biotechnology Collaborate To Advance VIR-5500

Sanofi SA

23/02/2026 22:00

Feb 23 (Reuters) - Astellas Pharma Inc 4503.T:

ASTELLAS PHARMA: CO & VIR BIOTECHNOLOGY ENTERED GLOBAL STRATEGIC COLLABORATION TO ADVANCE VIR-5500 FOR TREATMENT OF PROSTATE CANCER

ASTELLAS: CO WILL OBTAIN EXCLUSIVE RIGHTS TO COMMERCIALIZE VIR-5500 EXCLUDING-U.S.

ASTELLAS: TO LEAD COMMERCIALIZATION OF VIR-5500 IN THE U.S. WITH VIR BIOTECHNOLOGY RETAINING OPTION TO CO-PROMOTE

ASTELLAS: VIR BIOTECHNOLOGY TO GET $335 MILLION IN UPFRONT & NEAR-TERM MILESTONE PAYMENTS, WILL SPLIT U.S. PROFIT/LOSS EQUALLY WITH ASTELLAS

ASTELLAS: ELIGIBLE TO RECEIVE UP TO ADDITIONAL $1.37 BILLION IN DEVELOPMENT, REGULATORY & SALES MILESTONES

ASTELLAS: UNDER TERMS OF VIR BIOTECHNOLOGY'S LICENSING DEAL WITH SANOFI, A PORTION OF CERTAIN COLLABORATION PROCEEDS WILL BE SHARED WITH SANOFI

Further company coverage: 4503.T